Cypherpunk Technologies Inc (CYPH) Stock Price, Quote & News

Company Profile

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an optio...

Industry: Asset Management

Sector: Financial Services

Phone: 617 714 0360

Website: www.leaptx.com

Address:

47 Thorndike Street, Suite B1-1, Cambridge, United States

deano361 Dec. 25 at 2:26 AM

$CYPH $ZEC.X what’s coming here will blow Minds !! https://x.com/mert/status/2003908108490625044?s=46&t=5ZlRqS0Wfi9BNWKligb-Qw

1 · Reply

deano361 Dec. 24 at 9:21 PM

$ZEC.X Trading in Binance and people locking up supply !! $CYPH https://x.com/jswihart/status/2003913204720881996?s=46&t=5ZlRqS0Wfi9BNWKligb-Qw

0 · Reply

MegaTrade22 Dec. 24 at 7:21 PM

$CYPH Tax write off, I still like the stock but I’ll revisit in the near future. I’m not a fan of dilution. GL everyone 🤝 NFA / JMO

0 · Reply

losingitall_ Dec. 24 at 6:35 PM

$CYPH Go back to $1.1, & I’ll buy back in. This thing can’t decide what it wants to do.

0 · Reply

Dulge_Gappana Dec. 24 at 5:18 PM

$CYPH when

0 · Reply

Proletareart Dec. 24 at 4:59 PM

$ZEC.X $CYPH @BongoZongo @RichThroughLIRA @ShyGlizzy get your Wendy’s applications ready

0 · Reply

deano361 Dec. 24 at 4:58 PM

$CYPH short here equal low IQ

0 · Reply

DubLad76 Dec. 24 at 4:57 PM

$ZEC.X fantastic to see $ZEC.X now available to trade on Binance. Just started trading there today. Will bring lots more eager investors to the table. $CYPH

1 · Reply

deano361 Dec. 24 at 4:52 PM

$CYPH go Zec go!!

0 · Reply

LongLife1 Dec. 24 at 4:31 PM

$CYPH epic dilution

1 · Reply

Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor

Dec 15, 2025, 12:59 PM EST - 9 days ago

Cypherpunk Technologies Inc. (CYPH) Leap Therapeutics, Inc. - Shareholder/Analyst Call Prepared Remarks Transcript

Dec 9, 2025, 7:00 AM EST - 15 days ago

Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor

Nov 12, 2025, 8:00 AM EST - 6 weeks ago

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:00 AM EST - 6 weeks ago

Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

Oct 20, 2025, 7:00 AM EDT - 2 months ago

Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

Oct 9, 2025, 7:00 AM EDT - 2 months ago

Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Oct 6, 2025, 9:00 AM EDT - 2 months ago

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Sep 25, 2025, 7:00 AM EDT - 3 months ago

Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

Aug 14, 2025, 7:00 AM EDT - 4 months ago

Leap Therapeutics Reports Second Quarter 2025 Financial Results

Jun 23, 2025, 7:00 AM EDT - 6 months ago

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

May 13, 2025, 7:00 AM EDT - 8 months ago

Leap Therapeutics Reports First Quarter 2025 Financial Results

Apr 25, 2025, 1:00 PM EDT - 8 months ago

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Apr 15, 2025, 7:00 AM EDT - 9 months ago

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Mar 31, 2025, 1:42 PM EDT - 9 months ago

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

Mar 26, 2025, 1:29 PM EDT - 9 months ago

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Mar 26, 2025, 7:05 AM EDT - 9 months ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 26, 2025, 7:00 AM EDT - 9 months ago

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Jan 28, 2025, 7:00 AM EST - 11 months ago

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Jan 6, 2025, 7:01 AM EST - 1 year ago

Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer

Jan 6, 2025, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Second Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports First Quarter 2024 Financial Results

Apr 11, 2024, 8:30 AM EDT - 1 year ago

Leap Therapeutics Announces $40 Million Private Placement

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 16, 2024, 5:05 PM EST - 2 years ago

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Jan 3, 2024, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 7:00 AM EST - 2 years ago

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Dec 11, 2023, 4:05 PM EST - 2 years ago

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Nov 21, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

Nov 13, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics to Participate at Upcoming Investor Conferences

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Jul 12, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Jun 20, 2023, 12:30 PM EDT - 2 years ago

Leap Therapeutics Announces Reverse Stock Split

May 25, 2023, 5:10 PM EDT - 2 years ago

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

May 15, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports First Quarter 2023 Financial Results

Apr 12, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 16, 2023, 4:05 PM EDT - 3 years ago

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

Jan 17, 2023, 8:00 AM EST - 3 years ago

Leap Therapeutics Acquires Flame Biosciences

Jan 11, 2023, 7:00 AM EST - 3 years ago

Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference

Nov 21, 2022, 7:00 AM EST - 3 years ago

Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference

deano361 Dec. 25 at 2:26 AM

$CYPH $ZEC.X what’s coming here will blow Minds !! https://x.com/mert/status/2003908108490625044?s=46&t=5ZlRqS0Wfi9BNWKligb-Qw

1 · Reply

deano361 Dec. 24 at 9:21 PM

$ZEC.X Trading in Binance and people locking up supply !! $CYPH https://x.com/jswihart/status/2003913204720881996?s=46&t=5ZlRqS0Wfi9BNWKligb-Qw

0 · Reply

MegaTrade22 Dec. 24 at 7:21 PM

$CYPH Tax write off, I still like the stock but I’ll revisit in the near future. I’m not a fan of dilution. GL everyone 🤝 NFA / JMO

0 · Reply

losingitall_ Dec. 24 at 6:35 PM

$CYPH Go back to $1.1, & I’ll buy back in. This thing can’t decide what it wants to do.

0 · Reply

Dulge_Gappana Dec. 24 at 5:18 PM

$CYPH when

0 · Reply

Proletareart Dec. 24 at 4:59 PM

$ZEC.X $CYPH @BongoZongo @RichThroughLIRA @ShyGlizzy get your Wendy’s applications ready

0 · Reply

deano361 Dec. 24 at 4:58 PM

$CYPH short here equal low IQ

0 · Reply

DubLad76 Dec. 24 at 4:57 PM

$ZEC.X fantastic to see $ZEC.X now available to trade on Binance. Just started trading there today. Will bring lots more eager investors to the table. $CYPH

1 · Reply

deano361 Dec. 24 at 4:52 PM

$CYPH go Zec go!!

0 · Reply

LongLife1 Dec. 24 at 4:31 PM

$CYPH epic dilution

1 · Reply

PrestigeC Dec. 24 at 3:36 PM

$CYPH this doesn’t matter. It would still be trading below mnav. That doesn’t change the market cap. Nav should have this around $105M at a 1.0 nav rate. $ZEC.X

1 · Reply

DubLad76 Dec. 24 at 3:28 PM

$CYPH it’s lags $ZEC.X. Though point is valid that they have been diluting to buy more $ZEC.X. What we need to see is that final PR stating they’ve got their 5%. Then $CYPH should rocket.🚀

0 · Reply

michaelburryburner Dec. 24 at 3:15 PM

$CYPH unfortunately today might confirm the dilution plan and to buy more $ZEC.X we should be up 5-10% today… maybe it’s the holidays…

1 · Reply

AllInn33 Dec. 24 at 3:08 PM

What happens to $CYPH when $ZEC.X hits $5,000? Holding and accumulating both for the long haul.

0 · Reply

michaelburryburner Dec. 24 at 3:06 PM

$CYPH wow $ZEC.X glad i own both

0 · Reply

BULL2471 Dec. 24 at 3:03 PM

$CYPH ZEC 442 holy moly

0 · Reply

BULL2471 Dec. 24 at 2:59 PM

$CYPH Huge news!!!

1 · Reply

Hegotgame88 Dec. 24 at 2:59 PM

$CYPH

0 · Reply

BULL2471 Dec. 24 at 2:57 PM

$CYPH $ZEC.X 435 squeeze imminent

0 · Reply

BULL2471 Dec. 24 at 2:48 PM

$CYPH $ZEC.X keep buying zero risk. Holding in ZEC 1.75+

0 · Reply

LongLife1 Dec. 24 at 2:48 PM

$CYPH the stock is getting diluted with the o/s around 140m , could fall back to 50cents so stay away

1 · Reply

BULL2471 Dec. 24 at 2:46 PM

$CYPH All shares sold short need to be bought back as $ZEC.X breaks out. Massive squeeze potential

1 · Reply

Market Cap	48.90M
Revenue (ttm)	0.00
Net Income (ttm)	-67.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,805,200
Avg Vol	30,043,270
Day's Range	N/A - N/A
Shares Out	41.44M
Stochastic %K	38%
Beta	-0.13
Analysts	Strong Buy
Price Target	N/A